Protagonist Therapeutics (PTGX) Tops Q4 EPS by 58c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 EPS of $0.44, $0.58 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $60 million versus the consensus estimate of $40 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture downgraded by TD Cowen on AI concerns